Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.

November 13, 2011
PresentationTivozanib

AACR-NCI-EORTC 2011: Tivozanib, a selective VEGFR TKI, potently blocks angiogenesis and growth in tumors that express a high level of VEGF-C and are refractory to VEGF-A blockade

November 6, 2011
PresentationTivozanib

EMUC 2011 – Results from Phase 1 trial of tivozanib combined with temsirolimus in patients with RCC

June 7, 2011
PresentationTivozanib

ASCO 2011: Final Analysis of the Phase 2 Randomized Discontinuation Trial of Tivozanib (AV-951) Versus Placebo in Patients With Renal Cell Carcinoma

June 7, 2011
PresentationTivozanib

ASCO 2011: Results From a Phase 1 Trial of Tivozanib (AV-951) Combined With Temsirolimus Therapy in Patients With Renal Cell Carcinoma

June 6, 2011
PresentationFiclatuzumab

ASCO 2011: Phase 2 Study of Ficlatuzumab (AV-299), an Anti-Hepatocyte Growth Factor Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With Non–Small Cell Lung Cancer

June 4, 2011
PresentationFiclatuzumab

ASCO 2011: Phase 1b Study of Ficlatuzumab (AV-299), an Anti-Hepatocyte Growth Factor Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC

1 … 12 13 14 15 16

Looking for medical information? Contact our Medical Information Team at

AVEOmedicalinformation@aveooncology.com.